BECN1 and melanoma: The CAGE-derived AQTGTGKT peptide inhibited CAGE binding to Beclin1 and enhanced the sensitivity to anticancer drugs in nonsmall cell lung cancer cells and melanoma cells, respectively (Kim et al., 2017a; Yeon et al., 2018).